Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Congratulations to EF Hutton on the Successful Closing of the Bone Biologics Corporation $5.0 Million Underwritten Public Offering

We are excited to announce that our client, EF Hutton, a division of Benchmark Investments, LLC, has successfully closed the underwritten public offering on behalf of Bone Biologics Corporation (NASDAQ: BBLG). This transaction is a testament to the relentless dedication and tireless work of all parties involved, especially the efforts of our exemplary legal team in collaboration with EF Hutton.

This deal, encompassing the sale of 2,538,071 shares of common stock at a public offering price of $1.97 per share, has resulted in gross proceeds, prior to deducting underwriting discounts and commissions and other offering expenses, of approximately $5.0 million for Bone Biologics, a pioneer in the development of orthobiologic products for the spine fusion markets.

Our firm’s commitment to EF Hutton and, by extension, Bone Biologics, saw countless hours dedicated to meticulous preparation, legal analysis, and strategic guidance. Our attorneys' exceptional work ethic, combined with a deep understanding of the financial and legal landscape, led to a smooth and successful offering.

The public offering was completed in accordance with an effective registration statement on Form S-1 (No. 333-271558), previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC) on June 14, 2023. This accomplishment serves as a clear indication of the strategic direction and potential of Bone Biologics as they continue to advance their mission in regenerative medicine.

We wholeheartedly commend EF Hutton for their exemplary management of this public offering. Their commitment and diligence have played a crucial role in steering this complex process towards a successful conclusion, thereby enabling Bone Biologics to continue their work in regenerative medicine for bone and spinal fusion procedures.

As we congratulate EF Hutton, we reaffirm our commitment to delivering outstanding legal services that lead to exceptional results. We extend our congratulations to both EF Hutton and Bone Biologics, and we look forward to future collaborations with them and other innovative companies.